Le Lézard
Classified in: Health, Business
Subject: OTC

Moberg Pharma Publishes Information Document on the Proposed Divestment of the OTC-Business


STOCKHOLM, March 4, 2019 /PRNewswire/ -- On February 12th, 2019, it was announced that Moberg Pharma AB (publ) ("Moberg Pharma" or the "Company") has entered into agreement with RoundTable Healthcare Partners and Signet Healthcare Partners to divest its entire commercial operations. Further information regarding the proposed divestment of the OTC-business has today been published and is available in the form of an information document.

The information document describes the proposed transaction as well as the Company's continued operations following a divestment of the OTC-business. The information document contains among other things financial pro forma information in the form of income statement and balance sheet for 2018, the background and reasons for the proposed divestment and detailed information regarding the different elements of the transaction.

The information document is only available in Swedish. However, the pro forma information is available in English in the form of a translation. The information document and the translation are available on the Company's website, http://www.mobergpharma.com/investors/calendarpresentations.

The published information document is to be used for information purposes only and as a basis for assessing the consequences of the proposed divestment of the OTC-business of Moberg Pharma and actions related thereto, which are described in the information document. The information document does not contain or constitute an invitation or an offer to acquire, sell, subscribe for or otherwise trade in shares or other securities in Moberg Pharma. The published information document has not been approved by any regulatory authority and is not a prospectus.

CONTACT:

For additional information, please contact: 

Peter Wolpert, CEO
phone: Sweden: +46-707-35-7135
US: +1-908-432-2203
e-mail: [email protected] 

Anna Ljung, CFO
phone: +46-707-66-6030
e-mail: [email protected]

About this information              

The information was submitted for publication, through the contact persons set out above, at 8.30 a.m. (CET) on March 4th, 2019. 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/moberg-pharma/r/moberg-pharma-publishes-information-document-on-the-proposed-divestment-of-the-otc-business,c2754647

The following files are available for download:

https://mb.cision.com/Main/1662/2754647/1001269.pdf

Moberg Pharma publishes information document on the proposed divestment of the OTC-business

https://mb.cision.com/Public/1662/2754647/8e8cb28e00e70b68.pdf

Information Document 190304

https://mb.cision.com/Public/1662/2754647/bf31d1f4c6b720ad.pdf

English translation of pro forma 190304

SOURCE Moberg Pharma


These press releases may also interest you

at 02:34
SciBase Holding AB ("SciBase") (STO: SCIB), a pioneer in skin cancer detection and prevention, and prediction in dermatology, further deepens their commitment to patients and dermatologists during US Skin Cancer Awareness Month by highlighting the...

at 02:14
Implantica AG (publ.), a medtech company at the forefront of bringing advanced technology into the body, announces that Dra. Beatriz Guil of Universitario de Canarias in the Canary Islands and Dr. Carlos Milliani of Universitario de Fuenlabrada in...

at 02:00
YourBio Health, a Boston-based pioneer in remote, capillary whole blood collection technology, congratulates Myriad Genetics for having sold one million of its leading SneakPeek® Tests. Since 2021, YourBio Health is pleased to have contributed over...

at 02:00
Recognized as One of Houston's Best Luxury Spas Mirror Mirror Beauty...

at 01:30
PARIS, FRANCE, 2 May 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, announced today the appointment of Keira Driansky as EVP, President of North America, effective May 13, 2024. She will serve on the...

at 01:00
Management Report1 Q1 2024 highlights Strong performance in Perfumery & Beauty on good demand developmentGood performance in Taste, Texture & Health underpinned by market recoveryHealth, Nutrition & Care was soft, with improving momentum by end of...



News published on and distributed by: